Q-linea AB (publ) (OMX: QLINEA), a diagnostics company focused on developing and delivering solutions to diagnose infectious diseases accurately and rapidly, today announces the start of commercial evaluation of the fully automated ASTar® Instrument and first ASTar Consumable kit, delivering rapid antimicrobial susceptibility results for gram-negative bacteria, including fastidious, directly from positive blood cultures.
“We are happy to announce that we, within a month of the CE-mark, have started the commercial evaluation of ASTar in Europe with the first system installation. It shows the dedication we have from Thermo Fisher Scientific and that all the preparations from both organizations have paid off. This is our first step in the commercial launch strategy for ASTar to support long-term successful commercialization. Thermo Fisher Scientific has a dedicated sales, marketing and service organization to support ASTar and I think this is very positive,” said Jonas Jarvius, CEO at Q-linea.
The ASTar Instrument and ASTar BC G- Kit offer the broadest combination of antimicrobials and dilution ranges in a single analysis for gram-negative bacteria. The test enables the analysis of both, fastidious and non-fastidious bacteria, for rapid and comprehensive results that support optimal treatment decisions.
If you would like to receive additional information regarding ASTar please contact Q-linea for the Swedish market www.qlinea.com/request-consultation and Thermo Fisher Scientific for other European countries www.thermofisher.com/se/en/home/global/forms/industrial/rapid-antimicrobial-susceptibility-testing.html.
The ASTar® Instrument and ASTar® BC G- Kit are CE-marked but not FDA 510(k)-cleared and not available for sale in the U.S.